 |
|
Cancer Mortality Following Treatment for Adult Hyperthyroidism
Elaine Ron, PhD;
Michele Morin Doody, MS;
David V. Becker, MD;
A. Bertrand Brill, MD;
Rochelle E. Curtis, MA;
Marlene B. Goldman, ScD;
Benjamin S. H. Harris III;
Daniel A. Hoffman, PhD;
William M. McConahey, MD;
Harry R. Maxon, MD;
Susan Preston-Martin, PhD;
M. Ellen Warshauer, MS;
F. Lennie Wong, PhD;
John D. Boice, Jr, ScD;
for the Cooperative Thyrotoxicosis Therapy Follow-up Study Group
JAMA. 1998;280:347-355.
Context.— High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic 131I to the development of cancer, its extensive medical use indicates the need for additional evaluation.
Objective.— To evaluate cancer mortality among hyperthyroid patients, particularly after 131I treatment.
Design.— A retrospective cohort study.
Setting.— Twenty-five clinics in the United States and 1 clinic in England.
Patients.— A total of 35,593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with 131I.
Main Outcome Measure.— Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism.
Results.— Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86).
Conclusions.— Neither hyperthyroidism nor 131I treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following 131I treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, 131I appears to be a safe therapy for hyperthyroidism.
From the Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md (Drs Ron, Wong, and Boice and Mss Doody and Curtis); The New York Hospital–Cornell Medical Center, New York, NY (Dr Becker and Ms Warshaver); Vanderbilt University, Nashville, Tenn (Dr Brill); Harvard University School of Public Health, Boston, Mass (Dr Goldman); Research Triangle Institute, Research Triangle Park, NC (Mr Harris ); George Washington University, Washington, DC (Dr Hoffman); Mayo Clinic, Rochester, Minn (Dr McConahey); University of Cincinnati Medical Center, Cincinnati, Ohio (Dr Maxon); and the University of Southern California, Los Angeles (Dr Preston-Martin). Dr Wong is currently a private statistical consultant in Burbank, Calif. Dr Boice is currently with the International Epidemiology Institute, Rockville, Md.
Dr Harris is deceased.
RELATED ARTICLE
Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years?
David S. Cooper
JAMA. 1998;280(4):375-376.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Cohort Study of Thyroid Cancer and Other Thyroid Diseases after the Chornobyl Accident: Dose-Response Analysis of Thyroid Follicular Adenomas Detected during First Screening in Ukraine (1998-2000)
Zablotska et al.
Am J Epidemiol 2008;167:305-312.
ABSTRACT
| FULL TEXT
Cardiovascular and Cancer Mortality after Radioiodine Treatment of Hyperthyroidism
Vanderpump
J. Clin. Endocrinol. Metab. 2007;92:2033-2035.
FULL TEXT
Increased Cardiovascular and Cancer Mortality after Radioiodine Treatment for Hyperthyroidism
Metso et al.
J. Clin. Endocrinol. Metab. 2007;92:2190-2196.
ABSTRACT
| FULL TEXT
An Optimal Treatment for Pediatric Graves' Disease Is Radioiodine
Rivkees and Dinauer
J. Clin. Endocrinol. Metab. 2007;92:797-800.
ABSTRACT
| FULL TEXT
The Optimal Treatment for Pediatric Graves' Disease Is Surgery
Lee et al.
J. Clin. Endocrinol. Metab. 2007;92:801-803.
FULL TEXT
Treatment of Thyrotoxicosis
Iagaru and McDougall
JNM 2007;48:379-389.
ABSTRACT
| FULL TEXT
The management of thyrotoxicosis in a pre-pubertal child with 18p deletion syndrome
Dharmaraj and Grueters
Eur J Endocrinol 2006;155:S145-S147.
ABSTRACT
| FULL TEXT
131I Ablation Treatment in Young Females After the Chernobyl Accident
Travis and Stabin
JNM 2006;47:1723-1727.
ABSTRACT
| FULL TEXT
Patient Misconceptions and Ethical Challenges in Radioactive Iodine Scanning and Therapy.
Rosenthal
J. Nucl. Med. Technol. 2006;34:143-150.
ABSTRACT
| FULL TEXT
What to tell patients about radioiodine therapy.
Cuthbertson and Davidson
BMJ 2006;333:271-272.
FULL TEXT
Radioiodine therapy for hyperthyroidism
DTB 2006;44:44-48.
ABSTRACT
| FULL TEXT
Mortality and Vascular Outcomes in Patients Treated for Thyroid Dysfunction
Flynn et al.
J. Clin. Endocrinol. Metab. 2006;91:2159-2164.
ABSTRACT
| FULL TEXT
Thyroid hormone in health and disease
Boelaert and Franklyn
J Endocrinol 2005;187:1-15.
ABSTRACT
| FULL TEXT
Thyroid Neoplasia, Autoimmune Thyroiditis, and Hypothyroidism in Persons Exposed to Iodine 131 From the Hanford Nuclear Site
Davis et al.
JAMA 2004;292:2600-2613.
ABSTRACT
| FULL TEXT
Juvenile thyrotoxicosis; can we do better?
Birrell and Cheetham
Arch. Dis. Child. 2004;89:745-750.
ABSTRACT
| FULL TEXT
Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism
Jonsson and Mattsson
Radiat Prot Dosimetry 2004;108:107-114.
ABSTRACT
| FULL TEXT
Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias
Hermida et al.
Europace 2004;6:169-174.
ABSTRACT
| FULL TEXT
Influence of Iodine-131 Dose on the Outcome of Hyperthyroidism in Children
Rivkees and Cornelius
Pediatrics 2003;111:745-749.
ABSTRACT
| FULL TEXT
Diagnosis and management of Graves' disease
Ginsberg
CMAJ 2003;168:575-585.
ABSTRACT
| FULL TEXT
How Should the Dose of Iodine-131 Be Determined in the Treatment of Graves' Hyperthyroidism?
Kalinyak and McDougall
J. Clin. Endocrinol. Metab. 2003;88:975-977.
FULL TEXT
Management of Simple Nodular Goiter: Current Status and Future Perspectives
Hegedus et al.
Endocr. Rev. 2003;24:102-132.
ABSTRACT
| FULL TEXT
Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-Specific Therapeutic Targets
Fagin
Endocrinology 2002;143:2025-2028.
FULL TEXT
Graves' Disease
Weetman
NEJM 2000;343:1236-1248.
FULL TEXT
Primary Hodgkin's disease of the CNS in an immunocompetent patient: A case study and review of the literature
Biagi et al.
Neuro Oncol 2000;2:239-243.
ABSTRACT
The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function
Bonnema et al.
J. Clin. Endocrinol. Metab. 1999;84:3636-3641.
ABSTRACT
| FULL TEXT
Radioiodine Therapy for Multinodular Toxic Goiter
Nygaard et al.
Arch Intern Med 1999;159:1364-1368.
ABSTRACT
| FULL TEXT
The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment
Rivkees et al.
J. Clin. Endocrinol. Metab. 1998;83:3767-3776.
FULL TEXT
Long-Term Consequences of I-131 Are Minor
JWatch General 1998;1998:5-5.
FULL TEXT
Radioiodine for Hyperthyroidism: Where Do We Stand After 50 Years?
Cooper
JAMA 1998;280:375-376.
FULL TEXT
|
